ANIKA THERAPEUTICS, INC.

(ANIK)
  Report
Delayed Nasdaq  -  05/25 04:00:00 pm EDT
21.60 USD   +2.71%
05/20SECTOR UPDATE : Health Care Stocks Gain Premarket Friday
MT
05/20SECTOR UPDATE : Health Care
MT
05/20Anika Therapeutics Says FDA Approves X-Twist System for Soft Tissue Repair
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Tranche Update on Anika Therapeutics, Inc.'s Equity Buyback Plan announced on May 2, 2019.

11/05/2021 | 05:06am EDT

From July 1, 2021 to September 30, 2021, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 590,751 shares, representing 4.15% for $30 million under the buyback announced on May 2, 2019.


© S&P Capital IQ 2021
All news about ANIKA THERAPEUTICS, INC.
05/20SECTOR UPDATE : Health Care Stocks Gain Premarket Friday
MT
05/20SECTOR UPDATE : Health Care
MT
05/20Anika Therapeutics Says FDA Approves X-Twist System for Soft Tissue Repair
MT
05/20Anika Receives FDA 510(k) Clearance for the X-Twist™ Knotless Fixation System, Ex..
GL
05/20Anika Receives FDA 510(k) Clearance for the X-Twist Knotless Fixation System, Expanding..
CI
05/20Anika Therapeutics Gets FDA OK for X-Twist Knotless Fixation System
DJ
05/13Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
05/09Anika to Participate in the UBS Global Healthcare Conference 2022
AQ
05/06ANIKA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION A..
AQ
05/05TRANSCRIPT : Anika Therapeutics, Inc., Q1 2022 Earnings Call, May 05, 2022
CI
More news
Analyst Recommendations on ANIKA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 154 M - -
Net income 2022 -11,0 M - -
Net Debt 2022 - - -
P/E ratio 2022 -28,5x
Yield 2022 -
Capitalization 314 M 314 M -
Capi. / Sales 2022 2,03x
Capi. / Sales 2023 1,85x
Nbr of Employees 297
Free-Float 98,2%
Chart ANIKA THERAPEUTICS, INC.
Duration : Period :
Anika Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ANIKA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 21,60 $
Average target price 37,50 $
Spread / Average Target 73,6%
EPS Revisions
Managers and Directors
Cheryl Renee Blanchard President, Chief Executive Officer & Director
Michael L. Levitz Chief Financial Officer, Treasurer & EVP
Jeffery S. Thompson Chairman
Mira Leiwant VP-Quality, Regulatory & Clinical Affairs
Steven W. Ek Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ANIKA THERAPEUTICS, INC.-41.31%306
CSL LIMITED-5.70%93 360
SAMSUNG BIOLOGICS CO.,LTD.-7.97%45 499
BIOGEN INC.-15.58%29 662
WUXI BIOLOGICS (CAYMAN) INC.-42.63%28 538
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-28.05%21 450